Back From the Dead: What Dog Cloning Means for Our Human Future
By Osagie K. Obasogie,
Alternet
| 06. 16. 2008
Good Morning America recently televised a world exclusive that caught many pet owners' attention: Dog cloning is now commercially available for people who want to bring their dead and dying companions back to life. Brought to you by BioArts International, a Northern California biotech startup, man and his dead best friend can now be, as the company's marketing slogan states, "Best Friends Again." And again. And again.
But it'll cost you. Rather than taking orders, BioArts will auction off five dog cloning slots in mid-June. Bids start at $100,000.
Despite Good Morning America's numerous awards for excellence in televised journalism, its coverage of this story was not its finest moment. A number of omissions and oversights led the segment to present dog cloning as a largely unproblematic way to deal with the grief of our pets' inevitable deaths. But several untold stories behind this story need to be put front and center.
The ABC morning show presented BioArts' CEO Lou Hawthorne as the next in a long line of pioneering Californian bio executives. But rather than being a new venture...
Related Articles
What We Inherit by Sam Trejo and Daphne O. Martschenko; and Original Sin by Kathryn Paige Harden have a great deal in common, with substantial differences in style and emphasis. Both books attempt, in different ways, to show the reader just where current research into human genomics stands, where that might be going, and why the authors are interested. In short, the influence of genomic research on our societies is already large and seems likely to change them in ways...
By Dan Falk, Nautilus | 08.20.2026
The pseudoscience of eugenics, founded on the mistaken notion that nature envisions some “right” combination of genes, and that selective breeding can improve the human race, is making a comeback. While the heyday of eugenics was a century ago, the...
By Emily Packard Dawson and Lainie Friedman Ross, MedPage Today | 08.18.2026
Few things evoke a greater sense of desperation than a parent seeking an experimental treatment for their child. That desperation can make even extraordinary risks seem worth taking. This dynamic has come into stark relief after Mei, a 6-year-old girl...
By Editors, Nature | 08.18.2026
Shinya Yamanaka doesn’t see himself as a celebrity. But people do recognize the stem-cell researcher when he’s out for a run, often while training for a marathon, on the streets of Kyoto, Japan.
Many of them call out words of...
